| MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN Patent applications |
| Patent application number | Title | Published |
| 20120128704 | REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF - The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin. | 05-24-2012 |
| 20100255041 | REMEDY FOR THE TREATMENT OF CARDIO-VASCULAR DISEASES OR DISORDERS - Disclosed is the use of inhibitors of β-catenin expression or activity or modulators downregulating β-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells. | 10-07-2010 |
| 20090220469 | PEPTIDES AGAINST AUTOANTIBODIES ASSOCIATED WITH GLAUCOMA AND USE OF THESE PEPTIDES - The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma. | 09-03-2009 |
| 20090105186 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases - The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said β-L-nucleoside analogs. | 04-23-2009 |
| 20090023662 | Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection - The invention relates to a method for detecting autoantibodies associated with humoral kidney rejection, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating humoral kidney rejection. | 01-22-2009 |
| 20080292550 | Fluorinated 3'-Deoxythymidine Derivatives, a Method for Their Preparation and Their Use - The invention relates to new side chain-fluorinated 3′-deoxythymidine derivatives of the general formula I | 11-27-2008 |